Evaluation of po suvorexant for delirium in ICU ventilated patients

Evaluation of po suvorexant for delirium in ICU ventilated patients - Evaluation of po suvorexant in ICU patients

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024796

Enrollment

Registered

2016-11-11

Start date

2016-11-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

insomnia

Interventions

Administration of suborexant via gastric tube(half dose) Administration of suborexant via gastric tube

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient who need mechanical ventilation and expected to stay ICU for 24 hours

Exclusion criteria

Exclusion criteria: ?Severe liver disfunction ?Patient who need continuous sedation throughout day ?Gastrointestinal dysfunction

Design outcomes

Primary

Measure	Time frame
frequency of insomnia, dose of sedative agents	—

Secondary

Measure	Time frame
frequency of delirium, dose of vasopressor	—

Countries

Japan

Contacts

Public ContactKansuke Koyama

Jichi Medical University hospital Department of Anesthesiology and Intensive care Medicine

k_koyama@jichi.ac.jp0285-58-7392

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026